Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

A CX3CR1 (fractalkine receptor) Small Molecular Antagonist (KAND567) Suppressed the Growth Promoting Effect of Monocytes on Chronic Lymphocytic Leukemia Cells

Mohammad Hojjat-Farsangi, Wen Zhong, Tom Mulder, Ann Svensson, Jeanette Lundin, Marzia Palma, Johan Schultz, Thomas Olin, Bjorn Wahlin, Anders Osterborg, Parviz Kokhaei, Hakan Mellstedt

Blood (2023) 142 (Supplement 1): 5716.

https://doi.org/10.1182/blood-2023-185953

Published: 2023

Journal Articles

Expression of the Fractalkine Receptor (CX3CR1) Is Significantly Increased in Immune Cells of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma patients with Active Disease

Marzia Palma, MD PhD, Tom A. Mulder, MD, Kia Heimersson, Li-Sophie Rathje, PhD, Thomas Olin, MSc,PhD, Johan Schultz, MSc,PhD, Håkan Mellstedt, MD PhD, Anders Österborg, MD PhD

Blood (2019) 134 (Supplement_1): 5445.

https://doi.org/10.1182/blood-2019-121818

Published: 2019

Journal Articles

ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells

Håkan Mellstedt, MD PhD Prof., Amineh Ghaderi, MSc, Johanna Aschan, MSc, Fariba Mozaffari, MSc,PhD, Ali Moshfegh, MSc,PhD, Birgitta Sander, MD PhD Prof., Johan Schultz, MSc,PhD, Martin Norin, MSc,PhD, Thomas Olin, MSc,PhD, Elias Drakos, MD PhD Prof., George Z. Rassidakis, MD PhD Prof., Anders Österborg, MD PhD, Mohammad Hojjat-Farsangi, MSc,PhD

Blood (2019) 134 (Supplement_1): 5312.

https://doi.org/10.1182/blood-2019-129773

Published: 2019

Journal Articles

Diffuse Large B Cell Lymphoma (DLBCL) Expresses ROR1 and a ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Tumor Cells

Mohammad Hojjat-Farsangi, MSc,PhD, Amineh Ghaderi, MSc, AmirHossein Daneshmanesh, MD PhD, Jemina Lehto, MSc, Ali Moshfegh, MSc,PhD, Parviz Kokhaei, MSc,PhD, Jan Vågberg, MSc,PhD, Elisabeth Olsson, MSc,PhD, Charlotta Löfberg, MSc,PhD, Charlotta Carina Norström, MSc,PhD, Johan Schultz, MSc,PhD, Martin Norin, MSc,PhD, Thomas Olin, MSc,PhD, Elias Drakos, MD PhD Prof., George Z. Rassidakis, MD PhD Prof., Anders Österborg, MD PhD, Håkan Mellstedt, MD PhD Prof.

Blood (2019) 134 (Supplement_1): 2565.

https://doi.org/10.1182/blood-2019-126801

Published: 2019

Journal Articles

Reduction of Tumor Burden Rather Than Off-Target Effects Drives Changes in T-Cell Number and Profile during Prolonged Ibrutinib Treatment in Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

Marzia Palma, MD PhD, Kia Heimersson, Tom A. Mulder, MD, Barbro Näsman-Glaser, Anders Österborg, MD PhD Prof., Håkan Mellstedt, MD PhD

Blood (2018) 132 (Supplement 1): 4421.

https://doi.org/10.1182/blood-2018-99-110236

Published: 2018

Journal Articles

First-in-Class Oral Small Molecule Against the Tyrosine Kinase ROR1 (KAN0439834) Induced Significant Apoptosis of Chronic Lymphocytic Leukemia Cells

Mohammad Hojjat-Farsangi, MSc, PhD Assist. Prof., Amir Hossein Daneshmanesh, MD PhD, Fariba Mozaffari, MSc, PhD, Lotta Hansson, Jan Vågberg, PhD, Styrbjörn Byström, PhD, Elisabeth Olsson, PhD, Charlotta Löfberg, PhD, Charlotta Carina Norström, PhD, Johan Schultz, PhD, Martin Norin, PhD, Thomas Olin, PhD, Anders Österborg, MD PhD Prof., Ali Moshfegh, PhD, Hakan Mellstedt, MD PhD Prof.

Blood (2017) 130 (Supplement 1): 4320.

https://doi.org/10.1182/blood.V130.Suppl_1.4320.4320

Published: 2017

Journal Articles

Long-Term Treatment with Ibrutinib in Chronic Lymphocytic Leukemia Patients Normalizes CD3 + and CD8 + T Cells and Immune Checkpoints Expression but Gradually Leads to CD4 + T-Cell Depletion

Marzia Palma, MD PhD, Kia Heimersson, Barbro Näsman-Glaser, Håkan Mellstedt, MD PhD, Anders Österborg, MD PhD Prof.

Blood (2017) 130 (Supplement 1): 4322.

https://doi.org/10.1182/blood.V130.Suppl_1.4322.4322

Published: 2017

Journal Articles

T Cells from Chronic Lymphocytic Leukemia (CLL) Patients Display Dysregulated Expression of Immune Checkpoint Molecules and Activation Markers Mainly Restricted to CD4 + Cells and Correlated with Disease Activity

Marzia Palma, MDPhD, Giusy Gentilcore, MSc, Fariba Mozaffari, PhD, Kia Heimersson, Barbro Näsman-Glaser, Lotta Hansson, MD PhD, Anders Österborg, MDPhD, Håkan Mellstedt, MD PhD

Blood (2015) 126 (23): 4132.

https://doi.org/10.1182/blood.V126.23.4132.4132

Published: 2015

Journal Articles

In Vivo Effects of Lenalidomide on T Cell Proliferation and Immune Checkpoint Molecules in Patients with Advanced Stage CLL: Results from a Phase II Study

Maria Winqvist, MD, Fariba Mozaffari, PhD, Marzia Palma, MD PhD, Sandra Eketorp Sylvan, MD PhD, Hakan Mellstedt, MD PhD, Anders Osterborg, MD PhD, Jeanette Lundin, MD PhD

Blood (2015) 126 (23): 4164.

https://doi.org/10.1182/blood.V126.23.4164.4164

Published: 2015

Journal Articles

First-in-Class ROR1 Small Molecule Inhibitor (KAN0439834) Downregulated Wnt-Canonical and Non-Canonical Signaling Pathways and Induced Apoptosis of CLL Cells

Mohammad Hojjat-Farsangi, PhD, Ali Moshfegh, PhD, Amir Hossein Daneshmanesh, MD PhD, Jan Vågberg, Byström Styrbjörn, Johan Schultz, Elisabeth Olsson, Charlotta Löfberg, Carina Norström, Martin Norin, Thomas Olin, PhD, Anders Österborg, MD PhD, Håkan Mellstedt, MD PhD

Blood (2015) 126 (23): 2912.

https://doi.org/10.1182/blood.V126.23.2912.2912

Published: 2015

Journal Articles

Vaccination with Dendritic Cells Loaded with Autologous Leukemic Cells in Combination with Low-Dose Lenalidomide Induced Immune Responses in Chronic Lymphocytic Leukemia (CLL) Patients

Lotta Hansson, MD PhD, Marzia Palma, MD PhD, Lars Adamson, Harriet Ryblom, Barbro Näsman-Glaser, Ingrid Eriksson, Kia Heimersson, Giusy Gentilcore, Håkan Mellstedt, MD PhD, Anders Österborg

Blood (2014) 124 (21): 4685.

https://doi.org/10.1182/blood.V124.21.4685.4685

Published: 2014

Journal Articles

Regulation of Natural Killer Cell Responses By Dendritic Cells Via Lymphotoxin-Alpha, Interleukin-12, and Tumor Growth Factor-Beta

Dhifaf Sarhan, PhD, Marzia Palma, MD PhD, Yumeng Mao, Lars Adamson, Rolf Kiessling, MD PhD, Håkan Mellstedt, MD PhD, Anders Österborg, Andreas Lundqvist

Blood (2014) 124 (21): 4140.

https://doi.org/10.1182/blood.V124.21.4140.4140

Published: 2014

Journal Articles

Phosphorylation of Receptor Tyrosine Kinase ROR1 At Tyrosine 641, 646 and Serine 652 residues Might Be of Importance for the Survival of CLL Leukemic Cells

Mohammad Hojjat-Farsangi, Ph.D, Amir Hossein Daneshmanesh, MD, PhD, Martin Norin, Ph.D, Åsa Sandin, Ph.D, Abdul Salam Khan, Msc, Ali Moshfegh, PhD, Eva Rossmann, MD, Ph.D, Anders Osterborg, MD, PhD, Hakan Mellstedt, MD, Ph.D

Blood (2012) 120 (21): 3885.

https://doi.org/10.1182/blood.V120.21.3885.3885

Published: 2012

Journal Articles

ROR1 Isoforms Are Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) - a Survival Factor for CLL Cells

Hakan Mellstedt, MD, PhD., Mohammad Hojjat-Farsangi, PhD, Ladan Mansouri, MD, Anders Osterborg, MD, PhD, Hodjattallah Rabbani, PhD

Blood (2011) 118 (21): 1778.

https://doi.org/10.1182/blood.V118.21.1778.1778

Published: 2011

Journal Articles

A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease

Davide Bagnara, Matthew S. Kaufman, Carlo Calissano, Sonia Marsilio, Piers E. M. Patten, Rita Simone, Philip Chum, Xiao-Jie Yan, Steven L. Allen, Jonathan E. Kolitz, Sivasubramanian Baskar, Christoph Rader, Hakan Mellstedt, Hodjattallah Rabbani, Annette Lee, Peter K. Gregersen, Kanti R. Rai, Nicholas Chiorazzi

Blood (2011) 117 (20): 5463–5472.

https://doi.org/10.1182/blood-2010-12-324210

Published: 2011

Includes: Supplemental data

Journal Articles

T Cells from Patients with Chronic Lymphocytic Leukaemia Prevent Apoptosis of Autologous CLL Cells in a Dose- and Cell:Cell-Contact Dependent Fashion; Rationale for New Therapeutic Possibilities.

Eva Rossmann, MD, PhD, Parviz Kokhaei, PhD, Fariba Mozaffari, PhD, Marzia Palma, MD, Anders Osterborg, MD, PhD, Hakan Mellstedt, MD, PhD, A. Raja Choudhury, MSc, PhD

Blood (2008) 112 (11): 2071.

https://doi.org/10.1182/blood.V112.11.2071.2071

Published: 2008

Journal Articles

Comparison of Antigen-Loading Strategies for DC-Based Immunotherapy of B-CLL.

Hakan Mellstedt, M.D., Ph.D., Parviz Kokhaei, B.S., Anders Osterborg, M.D., Ph.D., Aniruddha Choudhury, Ph.D.

Blood (2004) 104 (11): 4821.

https://doi.org/10.1182/blood.V104.11.4821.4821

Published: 2004

Journal Articles

Long-Term Id Vaccination Combined with IL-12 or IL-12 and GM-CSF in Early Stage Multiple Myeloma Patients.

Lotta Hansson, M.D. Ph.D., Amir O. Abdalla, M.D., Hodjattallah Rabbani, Ph.D., Anders Osterborg, M.D. Ph.D, Hakan Mellstedt, M.D. Ph.D

Blood (2004) 104 (11): 1500.

https://doi.org/10.1182/blood.V104.11.1500.1500

Published: 2004

Journal Articles

Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia

Mohammad-Reza Rezvany, Mahmood Jeddi-Tehrani, Hans Wigzell, Anders Österborg, Håkan Mellstedt

Blood (2003) 101 (3): 1063–1070.

https://doi.org/10.1182/blood-2002-03-0746

Published: 2003

Journal Articles

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)

Jeanette Lundin, Eva Kimby, Magnus Björkholm, Per-Anders Broliden, Fredrik Celsing, Viktoria Hjalmar, Lars Möllgård, Peppy Rebello, Geoff Hale, Herman Waldmann, Håkan Mellstedt, Anders Österborg

Blood (2002) 100 (3): 768–773.

https://doi.org/10.1182/blood-2002-01-0159

Published: 2002

NARROW

A CX3CR1 (fractalkine receptor) Small Molecular Antagonist (KAND567) Suppressed the Growth Promoting Effect of Monocytes on Chronic Lymphocytic Leukemia Cells

Expression of the Fractalkine Receptor (CX3CR1) Is Significantly Increased in Immune Cells of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma patients with Active Disease

ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells

Diffuse Large B Cell Lymphoma (DLBCL) Expresses ROR1 and a ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Tumor Cells

Reduction of Tumor Burden Rather Than Off-Target Effects Drives Changes in T-Cell Number and Profile during Prolonged Ibrutinib Treatment in Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

First-in-Class Oral Small Molecule Against the Tyrosine Kinase ROR1 (KAN0439834) Induced Significant Apoptosis of Chronic Lymphocytic Leukemia Cells

Long-Term Treatment with Ibrutinib in Chronic Lymphocytic Leukemia Patients Normalizes CD3 + and CD8 + T Cells and Immune Checkpoints Expression but Gradually Leads to CD4 + T-Cell Depletion

T Cells from Chronic Lymphocytic Leukemia (CLL) Patients Display Dysregulated Expression of Immune Checkpoint Molecules and Activation Markers Mainly Restricted to CD4 + Cells and Correlated with Disease Activity

In Vivo Effects of Lenalidomide on T Cell Proliferation and Immune Checkpoint Molecules in Patients with Advanced Stage CLL: Results from a Phase II Study

First-in-Class ROR1 Small Molecule Inhibitor (KAN0439834) Downregulated Wnt-Canonical and Non-Canonical Signaling Pathways and Induced Apoptosis of CLL Cells

Vaccination with Dendritic Cells Loaded with Autologous Leukemic Cells in Combination with Low-Dose Lenalidomide Induced Immune Responses in Chronic Lymphocytic Leukemia (CLL) Patients

Regulation of Natural Killer Cell Responses By Dendritic Cells Via Lymphotoxin-Alpha, Interleukin-12, and Tumor Growth Factor-Beta

Phosphorylation of Receptor Tyrosine Kinase ROR1 At Tyrosine 641, 646 and Serine 652 residues Might Be of Importance for the Survival of CLL Leukemic Cells

ROR1 Isoforms Are Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) - a Survival Factor for CLL Cells

A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease

T Cells from Patients with Chronic Lymphocytic Leukaemia Prevent Apoptosis of Autologous CLL Cells in a Dose- and Cell:Cell-Contact Dependent Fashion; Rationale for New Therapeutic Possibilities.

Comparison of Antigen-Loading Strategies for DC-Based Immunotherapy of B-CLL.

Long-Term Id Vaccination Combined with IL-12 or IL-12 and GM-CSF in Early Stage Multiple Myeloma Patients.

Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only